The New Eugenics: The Case Against Genetically Modified Humans
By Marcy Darnovsky,
Different Takes (Spring 2000)
| 11. 30. 1999
Published by the Hampshire College Population and Development Program
At the cusp of dot-com frenzy and the biotech century, a group of influential scientists and pundits has begun zealously promoting a new bio-engineered utopia. In the world of their visionary fervor, parents will strive to afford the latest genetic "improvements" for their children. According to the advocates of this human future (or, as some term it, "post-human" future), the exercise of consumer preferences for offspring options will be the prelude to a grand achievement: the technological control of human evolution.
My first close encounter with this techno-eugenic enthusiasm was in a 1997 book written for an unconverted lay audience by Princeton geneticist Lee M. Silver. In Remaking Eden: Cloning and Beyond in a Brave New World (New York: Avon Books 1998), Silver spins out scenarios of a future in which affluent parents are as likely to arrange genetic enhancements for their children as to send them to private school.
Silver confidently predicts that upscale baby-making will soon take place in fertility clinics, where prospective parents will undergo an IVF procedure...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...